<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331093</url>
  </required_header>
  <id_info>
    <org_study_id>k2020033</org_study_id>
    <nct_id>NCT04331093</nct_id>
  </id_info>
  <brief_title>Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma</brief_title>
  <official_title>A Single-cencer,Phase II Study of Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Di Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Hospital of Jilin University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acral melanoma is a melanoma that affects acral areas of the skin, which is the most&#xD;
      prevalent site of melanoma in non-Caucasians.Data in this subgroup is scarce.This study is to&#xD;
      evalueate the efficiency and safety of Neoadjuvant SHR-1210 plus apatinib in this particular&#xD;
      group,menawhile to determine the predictive value for efficiency of several biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a&#xD;
      new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase&#xD;
      inhibitor (TKI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR</measure>
    <time_frame>3 months</time_frame>
    <description>Pathological complete response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>npCR</measure>
    <time_frame>3 months</time_frame>
    <description>Near pathological complete response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 months</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 Year RFS</measure>
    <time_frame>3 years</time_frame>
    <description>Recurrence free survival in 3 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acral Melanoma</condition>
  <arm_group>
    <arm_group_label>resectable stage III-IV Acral melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210+Apatinib</intervention_name>
    <description>Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg&#xD;
Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression</description>
    <arm_group_label>resectable stage III-IV Acral melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.18 to 75 years. 2. Clinically diagnosed or pathologically diagnosed, resectable stage&#xD;
        III-IV Acral melanoma with at least one measurable lesion that has not been treated locally&#xD;
        (according to RECISTv1.1, this measurable lesion is spiral CT (Or MRI scan with a long&#xD;
        diameter ≥10mm or an enlarged lymph node with a short diameter ≥15mm), patients with&#xD;
        metastasis can also be enrolled; 3. Have not received any anti-tumor medication before. 4.&#xD;
        ECOG score is 0 or 1. 5. Tumor tissue specimens must be provided for genetic testing&#xD;
        (preoperative biopsy / intraoperative tissue removal).&#xD;
&#xD;
        6. Expected survival time ≥ 12 weeks. 7. The level of organ function must meet the&#xD;
        following requirements (7 days before randomization):&#xD;
&#xD;
          -  Peripheral blood: absolute neutrophil count (≥) 1.5 × 109 / L, platelet count (≥) 100&#xD;
             × 109 // L, hemoglobin (Hb) ≥9g / dL (no blood transfusion within 14 days before&#xD;
             detection);&#xD;
&#xD;
               -  Liver: serum total bilirubin (≤) 1.5 × ULN, aspartate aminotransferase (AST) and&#xD;
                  alanine aminotransferase (ALT) ≤ 3 × ULN (or AST, ALT ≤ 5 × ULN);&#xD;
&#xD;
                    -  Serum creatinine ≤1.5 × ULN or endogenous creatinine clearance ≥50mL / min&#xD;
                       (using Cockcroft-Gault formula); ④. International normalized ratio (INR) and&#xD;
                       activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (only applicable to&#xD;
                       patients who have not received anticoagulant therapy and received&#xD;
                       anticoagulant therapy, and anticoagulant drugs should meet the treatment&#xD;
                       requirements);&#xD;
&#xD;
                       ⑤. Cardiac function is normal, that is, the result of ECG is normal or has&#xD;
                       no clinical significance. Left ventricular ejection fraction (LVEF) of&#xD;
                       cardiac ultrasound examination is&gt; 50%.&#xD;
&#xD;
                       8. Women of childbearing age must have a negative pregnancy test within 7&#xD;
                       days before treatment; males of reproductive capacity or women who are at&#xD;
                       risk of pregnancy must use effective contraception throughout the study&#xD;
                       period and continue contraception for 3 months after the end of treatment.&#xD;
&#xD;
                       9. Can swallow pills normally. 10. Voluntarily participate in the research&#xD;
                       and sign the informed consent form, with good compliance and willingness to&#xD;
                       cooperate with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have been treated with anti-PD-1, anti-PD-L1, VEGFRTKI;&#xD;
&#xD;
          2. Patients who are participating or are participating in clinical studies of other drugs&#xD;
             or treatments, within 4 weeks before enrollment (prior to randomization);&#xD;
&#xD;
          3. Patients who received major surgery, vaccines, and systemic hormone therapy within 4&#xD;
             weeks before the study began; and patients who received radiation therapy within 2&#xD;
             weeks;&#xD;
&#xD;
          4. In the past 3 years, other malignancies other than acral or mucosal melanoma, except&#xD;
             for cured skin basal cell carcinoma, skin squamous cell carcinoma, early prostate&#xD;
             cancer and cervical cancer;&#xD;
&#xD;
          5. Receive hematopoietic stimulating factors (such as granulocyte colony stimulating&#xD;
             factor (G-CSF) and erythropoietin) within 1 week before the start of the study.&#xD;
&#xD;
          6. HIV positive test;&#xD;
&#xD;
          7. Patients with active hepatitis B or C:&#xD;
&#xD;
             ①. In the case of HBsAg or HBcAb positive, additional HBVDNA testing (results above&#xD;
             the lower limit of detection specified by the study site).&#xD;
&#xD;
             ②. In the case of HCV antibody positive, perform additional HCVRNA detection.&#xD;
&#xD;
          8. Urine routine indicates urinary protein ≥ ++ and it has been confirmed that the amount&#xD;
             of urinary protein in 24 hours is&gt; 1.0g;&#xD;
&#xD;
          9. Suffering from high blood pressure and cannot be well controlled by antihypertensive&#xD;
             drugs (systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg);&#xD;
&#xD;
         10. Pleural effusion or ascites with clinical symptoms and symptomatic treatment;&#xD;
&#xD;
         11. People with ocular shape and central nervous system (CNS) metastasis;&#xD;
&#xD;
         12. Have a history of active tuberculosis;&#xD;
&#xD;
         13. Have any uncontrollable clinical problems, including but not limited to:&#xD;
&#xD;
             ①. Have autoimmune disease, or have a history of autoimmune disease or a syndrome&#xD;
             requiring systemic treatment with steroids / immunosuppressants, such as pituitary&#xD;
             inflammation, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism and thyroid&#xD;
             Hypofunction&#xD;
&#xD;
             ②. The following occurred within the first 6 months of randomization: 1) deep vein&#xD;
             thrombosis or pulmonary embolism; 2) percutaneous coronary intervention, acute&#xD;
             coronary syndrome, coronary artery bypass grafting; 3) cerebrovascular accident,&#xD;
             Transient ischemic attack.&#xD;
&#xD;
             ③. Other serious and uncontrolled companion diseases that may affect the compliance of&#xD;
             the agreement or the interpretation of the results, including active opportunistic or&#xD;
             progressive (severe) infection, uncontrolled diabetes, cardiovascular disease (graded&#xD;
             by the New York Heart Association) System-defined grade III or IV heart failure, grade&#xD;
             II heart block, myocardial infarction in the past 6 months, unstable arrhythmia or&#xD;
             unstable angina, cerebral infarction in the past three months, etc.). Or lung disease&#xD;
             (history of interstitial pneumonia, obstructive pulmonary disease, and symptomatic&#xD;
             bronchospasm);&#xD;
&#xD;
         14. Patients with any condition that affects swallowing the drug, and any condition that&#xD;
             affects the absorption of the research product in vivo, including any type of&#xD;
             gastrointestinal resection or surgery;&#xD;
&#xD;
         15. Previous stem cell transplant or organ transplant;&#xD;
&#xD;
         16. Women with childbearing potential or pregnant or lactating women with a positive serum&#xD;
             or urine pregnancy test within 7 days before the start of treatment;&#xD;
&#xD;
         17. Previously addicted to antipsychotic drugs, cannot be quit, or have a history of&#xD;
             mental illness;&#xD;
&#xD;
         18. Other serious, acute or chronic medical conditions or laboratory abnormalities may&#xD;
             increase the risks associated with participating in the research or may interfere with&#xD;
             the interpretation of the research results by investigators;&#xD;
&#xD;
         19. Other conditions that the researchers consider to be non-compliant or not applicable&#xD;
             to participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Di Wu, MD</last_name>
    <phone>13944888991</phone>
    <phone_ext>13944888991</phone_ext>
    <email>Wudi991202@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Di Wu, MD</last_name>
      <phone>13944888991</phone>
      <phone_ext>13944888991</phone_ext>
      <email>Wudi991202@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Hospital of Jilin University</investigator_affiliation>
    <investigator_full_name>Di Wu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

